Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
783 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, et al. · J Am Coll Cardiol · 2022Systematic Review
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I, Oreziak A, Barriales-Villa R, et al. · Lancet · 2020Clinical Trial, Phase III, Multicenter Study
- Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, et al. · J Am Coll Cardiol · 2022Systematic Review
- Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.
Desai MY, Owens AT, Abraham T, et al. · N Engl J Med · 2025Randomized Controlled Trial, Multicenter Study
- Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Garcia-Pavia P, Maron MS, Masri A, et al. · N Engl J Med · 2025Clinical Trial, Phase III, Equivalence Trial
- Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy.
Topriceanu CC, Pereira AC, Moon JC, et al. · Circulation · 2024Systematic Review, Meta-Analysis
- Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.
Davis BJ, Volk H, Nguyen O, et al. · J Am Heart Assoc · 2025Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials.
Aman A, Akram A, Akram B, et al. · Open Heart · 2025Systematic Review, Meta-Analysis
- Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
Dybro AM, Rasmussen TB, Nielsen RR, et al. · J Am Coll Cardiol · 2021Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
Heitner SB, Jacoby D, Lester SJ, et al. · Ann Intern Med · 2019Clinical Trial, Phase II, Multicenter Study
- Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
Ho CY, Day SM, Axelsson A, et al. · Nat Med · 2021Clinical Trial, Phase II, Randomized Controlled Trial
- Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.
Rossano JW, Canter C, Wolf CM, et al. · N Engl J Med · 2026Randomized Controlled Trial, Multicenter Study
- Quantitative Late Gadolinium Enhancement Cardiac Magnetic Resonance and Sudden Death in Hypertrophic Cardiomyopathy: A Meta-Analysis.
Kiaos A, Daskalopoulos GN, Kamperidis V, et al. · JACC Cardiovasc Imaging · 2024Meta-Analysis, Research Support, Non-U.S. Gov't
- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
Desai MY, Wolski K, Owens A, et al. · Circulation · 2025Multicenter Study, Randomized Controlled Trial
- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
Desai MY, Owens A, Wolski K, et al. · JAMA Cardiol · 2023Multicenter Study, Randomized Controlled Trial
- Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials.
Fahim M, Eldawud D, Wahadneh O, et al. · Am J Cardiol · 2026Systematic Review, Meta-Analysis
- Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Coats CJ, Masri A, Nassif ME, et al. · J Am Heart Assoc · 2024Clinical Trial, Phase III, Multicenter Study
- Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Ho CY, Mealiffe ME, Bach RG, et al. · J Am Coll Cardiol · 2020Clinical Trial, Phase II, Multicenter Study
- Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Saberi S, Abraham TP, Choudhury L, et al. · JACC Heart Fail · 2025Clinical Trial, Phase III, Clinical Trial, Phase II
- Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
Hegde SM, Lester SJ, Solomon SD, et al. · J Am Coll Cardiol · 2021Clinical Trial, Phase III, Multicenter Study
- Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
Desai MY, Owens A, Geske JB, et al. · J Am Coll Cardiol · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Maron MS, Masri A, Nassif ME, et al. · J Am Coll Cardiol · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
Maron MS, Masri A, Choudhury L, et al. · J Am Coll Cardiol · 2023Randomized Controlled Trial, Clinical Trial, Phase II
- Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.
Zhou M, Ta S, Hahn RT, et al. · JAMA Cardiol · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy.
Masri A, Cardoso RN, Abraham TP, et al. · J Am Coll Cardiol · 2024Randomized Controlled Trial, Clinical Trial, Phase III
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.